AbbVie (ABBV) Net Cash Flow Growth (3y) (2015 - 2026)
AbbVie (ABBV) Net Cash Flow Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 38.95% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -49.89% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 33.59% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 37.67% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -129.17% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -10.13% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -98.96% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -51.84% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 8.91% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -68.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -49.89% |
| Mar 31, 2026 | 54.26% |
| Dec 31, 2025 | 46.30% |
| Sep 30, 2025 | -30.97% |
| Jun 30, 2025 | -19.90% |
| Mar 31, 2025 | 53.90% |
| Dec 31, 2024 | 11.19% |
| Sep 30, 2024 | -53.25% |
| Jun 30, 2024 | -58.57% |
| Mar 31, 2024 | 57.04% |
| Dec 31, 2023 | -43.13% |
| Sep 30, 2023 | 34.51% |
| Jun 30, 2023 | 27.21% |
| Mar 31, 2023 | -58.43% |
| Dec 31, 2022 | -27.87% |
| Sep 30, 2022 | -15.02% |
| Jun 30, 2022 | 109.53% |
| Mar 31, 2022 | -15.16% |
| Dec 31, 2021 | -49.82% |
| Sep 30, 2021 | -6.35% |